INmune Bio receives MHRA alignment for RDEB therapy filing

🇬🇧 Investing.com (GB) —
INmune Bio receives MHRA alignment for RDEB therapy filing

AI Summary

INmune Bio has received alignment from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with filing for a therapy targeting Recessive Dystrophic Epidermolysis Bullosa (RDEB). This step advances the treatment development process in the UK.

Markets Deals Health INmune Bio MHRA RDEB therapy regulatory alignment clinical development

Read original source →